Generated record quarterly net revenues of $211.4 million, representing year-over-year growth of 53.1% on a reported basis ...

Q2 2025 Earnings Conference Call August 5, 2025 9:00 PM ETCompany ParticipantsKazuya Kondo - Investor Relations ...

Recent positive recommendation by the Independent Data Monitoring Committee ("IDMC") to continue ELI-002 7P randomized Phase 2 study in pancreatic cancer without modifications to final analysis Event- ...

Generated record quarterly net revenues of $211.4 million, representing year-over-year growth of 53.1% on a reported basis and 37.0% on an organic basisTotal Rare Disease quarterly net revenues of ...